Company Encyclopedia
View More
name
KINDSTAR GLOBAL
09960.HK
Kindstar Globalgene Technology, Inc., an investment holding company, provides clinical testing services in the People’s Republic of China. The company offers its esoteric testing services for hematology, genetic diseases, gynecology, infectious diseases, neurology, and oncology diseases. It also provides testing services for the early warning, prevention, diagnosis, selection of therapeutic schedules, and evaluation for curative effect of specialized diseases. The company’s lab platforms comprise flow cytometry, cytogenetic, medical genomics, molecular biology, hematopathology, mass spectrum, pathology, clinical immunology, microbiology, and scientific research testing laboratories.
49.82 B
09960.HKMarket value -Rank by Market Cap -/-

Financial Score

20/12/2025 Update
D
Health Care ServicesIndustry
Industry Ranking20/28
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-3.60%D
    • Profit Margin-11.26%D
    • Gross Margin43.01%B
  • Growth ScoreD
    • Revenue YoY-3.72%D
    • Net Profit YoY-1216.55%E
    • Total Assets YoY3.85%C
    • Net Assets YoY-0.37%D
  • Cash ScoreD
    • Cash Flow Margin-888.44%E
    • OCF YoY-3.72%D
  • Operating ScoreD
    • Turnover0.24D
  • Debt ScoreB
    • Gearing Ratio26.93%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Kindstar Globalgene Technology Inc Unit To Buy 40% Of Huaxi Kindstar

    Kindstar Globalgene Technology Inc :UNIT TO BUY 40% OF HUAXI KINDSTAR FOR RMB12.4 MILLION

    Reuters·
    HK
    09960
    -1.67%
    Reuters·
    HK
    09960
    -1.67%

    KINDSTAR GLOBAL: Its subsidiary Wuhan Xino Medical Laboratory has passed CAP certification

    KINDSTAR GLOBAL news, the company's Wuhan Xino Medical Laboratory has passed CAP certification

    Zhitong·
    HK
    09960
    -1.67%
    Zhitong·
    HK
    09960
    -1.67%

    KINDSTAR GLOBAL turns from profit to loss in half-year with a loss of 36.073 million yuan

    KINDSTAR GLOBAL announced its interim results for the period ending June this year, with revenue of RMB 457 million, a year-on-year decrease of 3.5%. It turned from profit to a loss of RMB 36.073 million, compared to a profit of RMB 11.895 million in the same period last year; the loss per share was 3.78 cents. No dividend was declared

    AASTOCKS·
    HK
    09960
    -1.67%
    AASTOCKS·
    HK
    09960
    -1.67%

    KINDSTAR GLOBAL announced its interim results, with a gross profit of 197 million yuan, as all business segments achieved stable progress

    KINDSTAR GLOBAL released its interim results for the period ending June 30, 2025, with revenue of 457 million yuan and a gross profit of 197 million yuan. In the first half of the year, over 90 new hospital clients were added, with 48 new cooperative hospitals in the pediatric hematology sector. Sales of NGS testing products increased by more than 50%. The research department published 33 articles, applied for 67 patents, and added 56 new research and testing projects. The core product of the immune repertoire expanded to 160 institutions in blood cancer testing, with revenue growth of nearly 30%

    Zhitong·
    HK
    09960
    -1.67%
    Zhitong·
    HK
    09960
    -1.67%

    KINDSTAR GLOBAL: Tu Zanbing appointed as authorized representative

    KINDSTAR GLOBAL announced that Ms. Li Meiyi resigned as Co-Company Secretary and Company Authorized Representative, effective from August 29, 2025. Ms. Chai Haijie will serve as the sole Company Secretary, and Mr. Tu Zanbing has been appointed as the Authorized Representative, working alongside Ms. Chai to fulfill the responsibilities. Ms. Pan Jiaying will replace Ms. Li as the legal process agent

    Zhitong·
    HK
    09960
    -1.67%
    Zhitong·
    HK
    09960
    -1.67%
    © 2025 Longbridge｜Disclaimer